Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
SOLO Pharmaco-imaging: Preclinical Translational imaging
Non-invasive preclinical imaging to monitor the target expression and in vivo target engagement, the biodistribution of compounds, the effect of therapeutic treatments, and for the assessment of radiopharmaceuticals and translational biomarkers in precision medicine.
Access to multimodal imaging equipment, adapted to rodents and non-human primates
Optical imaging bioluminescence, fluorescence
Functional imaging MRI, DCE-MRI
Nuclear imaging PET, SPECT,combined MRI/TEP
Radiolabeling of chemicals or biological molecules (peptides, antibodies or other entities) adapted to study their fate and effects.
A dedicated expertise to design and perform specific pharmaco-imaging studies for your preclinical research programs – in various therapeutic areas – using technologies identical to those used in clinical nuclear medicine.